- Urodynamics
- Urology
- Men's Health
- Lower Urinary Tract Symptoms (LUTS)
- Benign Prostatic Hyperplasia (BPH)
- International Prostate Symptom Score (IPSS)
- Beta-3 Agonist
- Overactive Bladder (OAB)
How many prostate medications and procedures should a man try before anyone checks his bladder? Dr. Bilal Chughtai has met men who worked through an alpha blocker, add-on medications, a minimally invasive prostate procedure, and even resective surgery before anyone named overactive bladder as part of the problem. On this episode of BackTable Urology, Dr. Anjali Kapur, urogynecologist at Hackensack Meridian Health, welcomes Dr. Chughtai, chief of urology at Northwell Health's Plainview and Syosset hospitals, to rethink how urologists separate overactive bladder (OAB) from benign prostatic hyperplasia (BPH) in men. Dr. Chughtai explains how he reads the storage and voiding items of the International Prostate Symptom Score (IPSS), why he usually starts with a beta-3 agonist rather than an anticholinergic, how he trims polypharmacy one medication holiday at a time, and when urodynamics helps decide whether to treat the prostate, the bladder, or both.
This podcast is supported by
Timestamps
Resources
- Efficacy and Safety of Vibegron for Persistent Symptoms of Overactive Bladder in Men Being Pharmacologically Treated for Benign Prostatic Hyperplasia: Results From the Phase 3 Randomized Controlled COURAGE Trial. J Urol. 2024
- Vibegron for overactive bladder in men with benign prostatic hyperplasia/obstruction: insights from the COURAGE trial. Transl Androl Urol. 2025
- Lower Urinary Tract Symptoms Following Transurethral Resection of Prostate. Curr Urol Rep. 2018
- 5-year outcome of surgical resection and watchful waiting for men with moderately symptomatic benign prostatic hyperplasia: a Department of Veterans Affairs cooperative study. J Urol. 1998
- The AUA/SUFU Guideline on the Diagnosis and Treatment of Idiopathic Overactive Bladder
- BackTable Urology Episode 138: Hood-Sparing & Greenlight Laser Therapy in BPH Management
- Dr. Bilal Chughtai, BackTable Urology contributor page
- Dr. Anjali Kapur, BackTable Urology contributor page
More about this episode
The two then turn to third-line therapy in men, including intradetrusor botulinum toxin, sacral neuromodulation, and tibial nerve stimulation, and to men whose storage symptoms persist or appear after an outlet procedure. Dr. Chughtai shares what the COURAGE trial of a beta-3 agonist added to BPH therapy taught him about asking men directly about urge incontinence, along with his goal of a 50% improvement in symptoms, the limits of questionnaires and bladder diaries, his research on OAB awareness in primary care, and the link between nocturia and sleep apnea. They close on the open question of when to treat the bladder before it changes, and why counseling should inform men without threatening them.


